

27 Sep 2022 | Analysis

Chinese-Language Podcast: ESMO

Plus, mRNA and inhaled COVID vaccines, exec moves

by Brian Yang

Special guest, Citeline's Annie Siu, discusses the recent ESMO meeting and Jiangsu Hengrui and BeiGene's PD-1 data for hepatocellular carcinoma in this latest episode of the Chinese-language China Biotech podcast.

China Biotech Podcast host Brian Yang talks to special guest Annie Siu, Citeline's director of content for APAC, with a focus on the recent European Society for Medical Oncology (ESMO) Congress 2022, in the latest edition of this Chinese-language podcast.

They discuss Citeline's on-the-ground coverage of ESMO and highlight immuno-oncology data readouts from two major Chinese developers, [Jiangsu Hengrui Medicine Co., Ltd.](#) and [BeiGene, Ltd.](#) in advanced hepatocellular carcinoma. (Also see "[ESMO: Positive Results Buoy Chinese Oncology Developers' Global Hopes](#)" - Scrip, 11 Sep, 2022.)

In particular, the current situation for HCC in China, such as incidence and mortality, and current treatment options for advanced patients, are looked at, along with treatment guidelines and recommendations.

In the second part of the podcast, Brian talks to Scrip's Shanghai-based senior reporter Dexter Yan about mRNA vaccine developments in China. (Also see "[New Front-Runner Emerges In China mRNA Booster Race](#)" - Scrip, 25 Aug, 2022.)

Also on the agenda are the first approval of an inhaled COVID-19 vaccine from [CanSino Biologics Inc.](#) (Also see "[China Approves World's First Inhaled COVID-19 Vaccine](#)" - Scrip, 9 Sep, 2022.), as well as recent executive moves at [Everest Medicines Limited](#).

XXXXXXXXXXXXXXXXXXXX

Citeline Annie Siu ESMO PD-1 HCC

CSCO

mRNA

SoundCloud

Annie Siu

Citeline, Biomedtracker Datamonitor Healthcare ESMO Oncology team Poster Trialtrove ESMO 9000 Biomedtracker Datamonitor Healthcare Planner

ESMO 2022 planner Biomedtracker ESMO 2022 podcast

ESMO 2022 Late breaking abstracts PD-1 inhibitor LBA35 “ 13 95 543 + PD-1 inhibitor BeiGene Rationale-301 674

2022 2 487 2016 HCC 80%

CSCO NHC NCCN HCC Trialtrove monotherapy combination HCC TACE

[Click here to explore this interactive content online](#) 